

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUA MEDICINE

華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2552)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of Hua Medicine (the “**Company**”) announces that on March 22, 2021, the Company granted share options (the “**Share Options**”) to employees of the Company (the “**Grantees**”) pursuant to the Company’s share option scheme which was conditionally approved and adopted on August 26, 2018 and effective beginning September 14, 2018 (the “**Share Option Scheme**”), subject to acceptance by the Grantees. The Share Options entitle the Grantees to subscribe for a total of 9,000,000 new shares with a nominal value of US\$0.001 each (the “**Shares**”) in the share capital of the Company.

Details of the Share Options granted are as follows:

Date of Grant:	March 22, 2021
Exercise price of Share Options granted:	HK\$4.984 per Share
Closing price of the Shares on the date of grant:	HK\$4.830 per Share
Number of Share Options granted:	9,000,000 (each Share Option shall entitle the holder thereof to subscribe for one (1) Share)
Validity period of the Share Options:	Ten (10) years from the date of grant

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, except for Dr. Li Chen (executive Director and chief executive officer of the Company) who has been granted 3,000,000 Share Options, all the other Grantees are neither a Director, chief executive nor substantial shareholder of the Company nor an associate (as defined in the Listing Rules) of any of them. The grant of Share Options to Dr. Li Chen has been approved by the independent non-executive Directors of the Company.

By Order of the Board
Dr. Li Chen
Chief Executive Officer and Executive Director

Hong Kong, March 22, 2021

As of the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Dr. Lian Yong Chen as non-executive Directors; and Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors.